IDEA 073

Drug Profile

IDEA 073

Latest Information Update: 20 Jun 2008

Price : $50

At a glance

  • Originator IDEA
  • Developer Celtic Pharma; IDEA
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Actinic keratosis; Skin disorders

Most Recent Events

  • 23 Feb 2006 IDEA 073 has been licensed to Celtic Pharma worldwide
  • 02 Jun 2005 No development reported - Phase-I for Actinic keratosis in Germany (unspecified route)
  • 02 Jun 2005 Preclinical trials in Skin disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top